RGBP (Regen BioPharma) Other Current Liabilities: $1.38 Mil (As of Mar. 2026)


What is Regen BioPharma Other Current Liabilities?

Regen BioPharma RGBP +100.00% Other Current Liabilities is $1.38 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

Regen BioPharma's other current liabilities for the quarter that ended in Mar. 2026 was $1.38 Mil.

Regen BioPharma's quarterly other current liabilities increased from Sep. 2025 ($2.18 Mil) to Dec. 2025 ($2.56 Mil) but then declined from Dec. 2025 ($2.56 Mil) to Mar. 2026 ($1.38 Mil).

Regen BioPharma's annual other current liabilities increased from Sep. 2023 ($1.42 Mil) to Sep. 2024 ($1.43 Mil) and increased from Sep. 2024 ($1.43 Mil) to Sep. 2025 ($2.18 Mil).

Regen BioPharma Other Current Liabilities Related Terms

Regen BioPharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Other Current Liabilities Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.89 3.55 1.42 1.43 2.18

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 1.80 2.18 2.56 1.38

Regen BioPharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1.38 Mil mean?
Regen BioPharma (RGBP) has a Other Current Liabilities of $1.38 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regen BioPharma.
Is Regen BioPharma's Other Current Liabilities too high?
Regen BioPharma's current Other Current Liabilities is $1.38 Mil.
How does Regen BioPharma's Other Current Liabilities compare to SIGY and ENDV?
Regen BioPharma's Other Current Liabilities of $1.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regen BioPharma. Regen BioPharma's current Other Current Liabilities is $1.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Other Current Liabilities is $1.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Other Current Liabilities is $1.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.